This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations
Martínez Romero, G.,
Peris Martí, J.F.,
Gomar Fayos, J.,
Navarro Gosalbez, M.,
Quintana Vargas, I.,
Muelas Tirado, J.
Objectives: Describe and evaluate atypical antipsychotics utilisation on the institutionalized elderly population of the Valencian Community and prevalence of associated metabolic alterations.; Material and Methods: Multicentre transversal descriptive study on medication utilisation and prevalence case-control of alterations of glycaemia, cholesterol and triglycerides. The statistical analysis of metabolic alterations is performed from the difference in prevalence […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]
A phase II trial of tideglusib in Alzheimer’s disease
Lovestone, Simon,
Boadab, Mercè,
Dubois, Bruno,
Hüll, Michael,
Rinne, Juha O.,
Huppertz, Hans-Jürgen,
Calero, Miguel,
Andrés, María V.,
Gómez-Carrillo, Belén,
Leon, Teresa,
del Seri, Teodoro
Background: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer’s disease (AD). Objective: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. Methods: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14–26) AD patients on cholinesterase inhibitor and/or memantine treatment […]
The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer’s disease
Lewis, John E.,
McDaniel, H. Reginald,
Agronin, Marc E.,
Loewenstein, David A.,
Riveros, Jorge,
Mestre, Rafael,
Martinez, Mairelys,
Colina, Niurka,
Abreu, Dahlia,
Konefal, Janet,
Woolger, Judi M.,
Ali, Karriem H.
Alzheimer’s disease (AD) is a leading killer of Americans, imparts a significant toll on the quality of life of the patient and primary caregiver, and results in inordinate costs in an already overburdened medical system. Prior studies on cholinesterase inhibitors among AD patients have shown minimal amelioration of disease symptoms and/or restoration of lost cognitive […]
Memantine improves goal attainment and reduces caregiver burden in Parkinson’s disease with dementia
Objective: Memantine, an uncompetitive antagonist of N‐methyl‐D‐aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson’s disease (PDD), although its role in improving patient‐reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim […]
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study
Laredo, Leonor,
Vargas, Emilio,
Blasco, Antonio Javier,
Aguilar, Maria Dolores,
Moreno, Alfonso,
Portolés, Antonio
Objectives: To explore the association between use of antipsychotics and risk of cerebrovascular accident (CVA) in individuals with dementia aged 65 and older.; Design: Population-based case-control study.; Setting: UK-based electronic primary care records in the General Practice Research Database (GPRD).; Participants: Individuals with dementia aged 65 and older registered in the database between January 1, […]
Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial
Lanctôt, Krista L.,
Chau, Sarah A.,
Herrmann, Nathan,
Drye, Lea T.,
Rosenberg, Paul B.,
Scherer, Roberta W.,
Black, Sandra E.,
Vaidya, Vijay,
Bachman, David L.,
Mintzer, Jacobo E.
Background: Little is known about the effect of methylphenidate (MPH) on attention in Alzheimer’s disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses.; […]